The DOI matches its Crossref record; 57 of the 60 references it cites were found in a registry or an index.
Androgen Receptor Gene CAG Repeat Length and Body Mass Index Modulate the Safety of Long-Term Intramuscular Testosterone Undecanoate Therapy in Hypogonadal Men
Abstract
CONTEXT: A reliable form of androgen substitution therapy regarding kinetics, tolerance, and restoration of androgenicity is paramount in hypogonadal men. Intramuscular injection of the long-acting ester testosterone undecanoate (TU) offers a new modality. OBJECTIVE: The objective of the study was to assess the safety of TU regarding metabolic and pharmacogenetic confounders. DESIGN: This was a longitudinal one-arm open observation trial. A minimum of five individual assessments was a prerequisite. Putative modulators of safety parameters entering regression models were nadir and/or delta total testosterone concentrations, body mass index, androgen receptor (AR) gene CAG repeat length, and age. SETTING: The study was conducted at an andrological outpatient clinic. PATIENTS: Patients included 66 hypogonadal men (mean age 38 +/- 9.9 yr). MAIN OUTCOME MEASURES: A total of 515 data time points each related to prostate, erythropoiesis, lipoproteins, and circulation during 118 treatment-years with 1000 mg TU at 10- to 14-wk intervals. RESULTS: Testosterone substitution resulted in significant decrements of serum levels of low-density lipoprotein-cholesterol, resting diastolic and systolic blood pressure, and heart rate. Erythropoiesis was stimulated and concentrations of high-density lipoproteincholesterol increased. Parameters remained stable after four injections. No adverse effects regarding the prostate were observed. Significantly increased hematocrit greater than 50% was predicted by enhanced androgen action (shorter AR CAG repeats per higher testosterone levels). However, insufficient androgen action (longer AR CAG repeats per lower testosterone levels) caused pathological safety parameters (high blood pressure, adverse lipid profiles). In addition, a body mass index 30 kg/m(2) or greater represents a clinically relevant factor for the occurrence of all pathological safety parameters. Risk calculations for obese patients and nonlinear pharmacogenetic models to tailor androgen substitution are presented. CONCLUSIONS: Testosterone substitution with im TU is generally well tolerated. Modifications of androgen action are due to both AR CAG repeats and testosterone levels. Adverse observations are mostly seen in obese patients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Prostate-specific antigen and volume rise, marginally, plateauing at 12 months; further increase should be related to aging rather than therapy.”
From Onset of effects of testosterone treatment and time span until maximum effects are achieved (2011) · cites this paper as [44]
In the citing paper
“The decrease in low-density lipoprotein cholesterol seems somewhat slower: after 3 months (35), after 40–44 weeks, (44) or after 12 months (42) with a maximum observed after 24 months (32).”
From Onset of effects of testosterone treatment and time span until maximum effects are achieved (2011) · cites this paper as [44]
In the citing paper
“An increase was found to occur after 3 months increasing further during 12 months (43), after 6 months, (35) or close to 1 year (44). Continuous increase was observed over 24 months (32).”
From Onset of effects of testosterone treatment and time span until maximum effects are achieved (2011) · cites this paper as [44]
In the citing paper
“A decrease in the resting heart rate occurred after 40–44 weeks (44).”
From Onset of effects of testosterone treatment and time span until maximum effects are achieved (2011) · cites this paper as [44]
In the citing paper
“The effects of testosterone on red blood cell formation (hemoglobin and hematocrit) are dose dependent (14, 82, 83) while higher age is also a factor (44).”
From Onset of effects of testosterone treatment and time span until maximum effects are achieved (2011) · cites this paper as [44]
In the citing paper
“An increase in prostate volume was noted after 3 months (86) and after 12 months (44).”
From Onset of effects of testosterone treatment and time span until maximum effects are achieved (2011) · cites this paper as [44]
Citations
Cites
A Critical Evaluation of Simple Methods for the Estimation of Free Testosterone in Serum
Vermeulen, A., Verdonck, L., & Kaufman, J. M. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.10.6079 · Cited by 3,824
Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer
Keating, N. L., O'Malley, A. J., & Smith, M. R. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.2497 · Cited by 1,455
Testosterone dose-response relationships in healthy young men
Bhasin, S., Woodhouse, L., Casaburi, R., Singh, A. B., Bhasin, D., Berman, N., Chen, X., Yarasheski, K. E., Magliano, L., Dzekov, C., et al. (2001) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.2001.281.6.e1172 · Cited by 967
Bhasin, S., Cunningham, G. R., Hayes, F. J., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., & Montori, V. M. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2847 · Cited by 965
Calof, O. M., Singh, A. B., Lee, M. L., Kenny, A. M., Urban, R. J., Tenover, J. L., & Bhasin, S. (2005) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/60.11.1451 · Cited by 728
Isidori, A. M., Giannetta, E., Greco, E. A., Gianfrilli, D., Bonifacio, V., Isidori, A., Lenzi, A., & Fabbri, A. (2005) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2005.02339.x · Cited by 695
Wang, C., Cunningham, G., Dobs, A., Iranmanesh, A., Matsumoto, A. M., Snyder, P. J., Weber, T., Berman, N., Hull, L., & Swerdloff, R. S. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-032006 · Cited by 656
Association of Specific Symptoms and Metabolic Risks with Serum Testosterone in Older Men
Zitzmann, M., Faber, S., & Nieschlag, E. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0401 · Cited by 552
Self-citationBhasin, S., Woodhouse, L., Casaburi, R., Singh, A. B., Mac, R. P., Lee, M., Yarasheski, K. E., Sinha-Hikim, I., Dzekov, C., Dzekov, J., et al. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1184 · Cited by 544
Effect of Testosterone Treatment on Body Composition and Muscle Strength in Men Over 65 Years of Age
Snyder, P. J. (1999) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.8.2647 · Cited by 531
Low Serum Testosterone and Mortality in Male Veterans
Shores, M. M., Matsumoto, A. M., Sloan, K. L., & Kivlahan, D. R. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.15.1660 · Cited by 489
Wang, C., Nieschlag, E., Swerdloff, R. S., Behre, H. M., Hellstrom, W. J. G., Gooren, L. J., Kaufman, J., Legros, J. J., Lunenfeld, B., Morales, Á., et al. (2008) · Journal of Andrology · doi:10.2164/jandrol.108.006486 · Cited by 443
Self-citationMarks, L. S., Mazer, N. A., Mostaghel, E., Hess, D. L., Dorey, F. J., Epstein, J. I., Veltri, R. W., Makarov, D. V., Partin, A. W., Bostwick, D. G., et al. (2006) · JAMA · doi:10.1001/jama.296.19.2351 · Cited by 400
Dobs, A. S. (1999) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.10.3469 · Cited by 381
Mhatre, A. N., Trifiro, M. A., Kaufman, M., Kazemi‐Esfarjani, P., Figlewicz, D. A., Rouleau, G. A., & Pinsky, L. (1993) · Nature Genetics · doi:10.1038/ng1093-184 · Cited by 357
Behre, H. M., Bohmeyer, J., & Nieschlag, E. (1994) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1994.tb03929.x · Cited by 335
Self-citationAndrology : male reproductive health and dysfunction
Nieschlag, E., Behre, H. M., & van Ahlen, H. (2001) · doi:10.1007/978-3-540-78355-8 · Cited by 319
Self-citationNieschlag, E. (2001) · Cambridge University Press eBooks · doi:10.1017/cbo9780511545221 · Cited by 317
Self-citationJw, F., Samuels, A. I., & La, M. (1971) · PubMed · Cited by 285
NIESCHLAG, E., SWERDLOFF, R., BEHRE, H. M., GOOREN, L. J., KAUFMAN, J. M., LEGROS, J. ‐., LUNENFELD, B., MORLEY, J. E., SCHULMAN, C., WANG, C., et al. (2005) · International Journal of Andrology · doi:10.1111/j.1365-2605.2005.00553.x · Cited by 282
Self-citationInhibition of p160-mediated coactivation with increasing androgen receptor polyglutamine length
Irvine, R. A. (2000) · Human Molecular Genetics · doi:10.1093/hmg/9.2.267 · Cited by 263
Zitzmann, M., Depenbusch, M., Gromoll, J., & Nieschlag, E. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1424 · Cited by 231
Self-citationThe CAG repeat polymorphism within the androgen receptor gene and maleness1
Zitzmann, M., & Nieschlag, E. (2003) · International Journal of Andrology · doi:10.1046/j.1365-2605.2003.00393.x · Cited by 228
Self-citationTestosterone replacement therapy: current trends and future directions
Nieschlag, E., Behre, H. M., Bouchard, P., Corrales, J. J., Jones, T. H., Stalla, G. K., Webb, S. M., & Wu, F. C. W. (2004) · Human Reproduction Update · doi:10.1093/humupd/dmh035 · Cited by 224
Self-citationLee, B. I., Nam, H. S., Heo, J. H., & Kim, D. I. (2001) · Cerebrovascular Diseases · doi:10.1159/000047697 · Cited by 223
Hsiao, P., Lin, D., Nakao, R., & Chang, C. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.29.20229 · Cited by 221
Estradiol, Testosterone, and the Risk for Hip Fractures in Elderly Men from the Framingham Study
Amin, S., Zhang, Y., Felson, D. T., Sawin, C. T., Hannan, M. T., Wilson, P. W. F., & Kiel, D. P. (2006) · The American Journal of Medicine · doi:10.1016/j.amjmed.2005.10.048 · Cited by 191
Schubert, M., Minnemann, T., Hübler, D., Rouskova, D., Christoph, A., Oettel, M., Ernst, M. E., Mellinger, U., Krone, W., & Jockenhövel, F. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0897 · Cited by 187
Dose-Dependent Effects of Testosterone on Regional Adipose Tissue Distribution in Healthy Young Men
Woodhouse, L. J., Gupta, N., Bhasin, M., Singh, A. B., Ross, R., Phillips, J., & Bhasin, S. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031492 · Cited by 173
Behre, H. M., Abshagen, K., Oettel, M., Hübler, D., & Nieschlag, E. (1999) · European Journal of Endocrinology · doi:10.1530/eje.0.1400414 · Cited by 155
Self-citationvon Eckardstein, S., & Nieschlag, E. (2002) · Journal of Andrology · doi:10.1002/j.1939-4640.2002.tb02249.x · Cited by 144
Self-citationObesity, mortality and cardiovascular disease in the Münster Heart Study (PROCAM)
Schulte, H. (1999) · Atherosclerosis · doi:10.1016/s0021-9150(99)00055-6 · Cited by 143
Nieschlag, E., Büchter, D., Von Eckardstein, S., Abshagen, K., Simoni, M., & Behre, H. M. (1999) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1999.00881.x · Cited by 140
Self-citationTestosterone treatment comes of age: new options for hypogonadal men
Nieschlag, E. (2006) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2006.02618.x · Cited by 137
Self-citationZeegers, M. P., Kiemeney, L. A. L. M., Nieder, A. M., & D, H. O. M. (2004) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.1765.13.11 · Cited by 132
Long‐term substitution therapy of hypogonadal men with transscrotal testosterone over 7–10 years
Behre, H. M., von Eckardstein, S., Kliesch, S., & Nieschlag, E. (1999) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1999.00705.x · Cited by 122
Self-citationZitzmann, M., Depenbusch, M., Gromoll, J., & Nieschlag, E. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021947 · Cited by 112
Self-citationHaematocrit, hypertension and risk of stroke
Wannamethee, S. G., Perry, I. J., & Shaper, A. G. (1994) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.1994.tb01050.x · Cited by 97
Testosterone and risk factors for cardiovascular disease in men.
Barrett-Connor, E. L. (1995) · PubMed · Cited by 89
Albertelli, M. A., Scheller, A., Brogley, M. A., & Robins, D. M. (2006) · Molecular Endocrinology · doi:10.1210/me.2006-0021 · Cited by 82
Nebido: a long-acting injectable testosterone for the treatment of male hypogonadism
Harle, L., Basaria, S., & Dobs, A. S. (2005) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.6.10.1751 · Cited by 80
Dobs, A. S., Bachorik, P. S., Arver, S., Meikle, A. W., Sanders, S. W., Caramelli, K. E., & Mazer, N. A. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.3.7285 · Cited by 73
Mechanisms of Disease: pharmacogenetics of testosterone therapy in hypogonadal men
Zitzmann, M. (2007) · Nature Clinical Practice Urology · doi:10.1038/ncpuro0706 · Cited by 67
Self-citationSerum Testosterone Levels and Arterial Blood Pressure in the Elderly
Fogari, R., Preti, P. S., Zoppi, A., Fogari, E., Rinaldi, A., Corradi, L., & Mugellini, A. (2005) · Hypertension Research · doi:10.1291/hypres.28.625 · Cited by 65
Androgen receptor polymorphism (CAG repeats) and androgenicity
Canale, D., Caglieresi, C., Moschini, C., Liberati, C. D., Macchia, E., Pinchera, A., & Martino, E. (2005) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2005.02354.x · Cited by 64
Contraceptive Steroids Influence the Hemostatic Activation State in Healthy Men
Zitzmann, M., Junker, R., Kamischke, A., & Nieschlag, E. (2002) · Journal of Andrology · doi:10.1002/j.1939-4640.2002.tb02272.x · Cited by 49
Self-citationRheological influences on thrombosis
Lowe, G. D. O. (1999) · Best Practice & Research Clinical Haematology · doi:10.1053/beha.1999.0035 · Cited by 45
Coviello, A. D., Lakshman, K. M., Mazer, N. A., & Bhasin, S. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0822 · Cited by 44
Dobs, A. S. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.3.1026 · Cited by 41
Transcriptional activation by the androgen receptor in X-linked spinal and bulbar muscular atrophy
Nakajima, H., Kimura, F., Nakagawa, T., Furutama, D., Shinoda, K., Shimizu, A., & Ohsawa, N. (1996) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(96)00142-6 · Cited by 36
PLATELET AGGREGATION, HAEMATOCRIT, AND FIBRINOGEN
Lowe, G. D. O., & Forbes, C. D. (1985) · The Lancet · doi:10.1016/s0140-6736(85)91414-x · Cited by 29
Wakisaka, N., Taira, Y.-I., Ishikawa, M., Nakamizo, Y., Kobayashi, K., Uwabu, M., Fukuda, Y., Taguchi, Y., Hama, T., & Kawakami, M. (2005) · Journal of Investigative Dermatology Symposium Proceedings · doi:10.1111/j.0022-202x.2005.10123.x · Cited by 23
Weinbauer, G. F., Partsch, C., Zitzmann, M., Schlatt, S., & Nieschlag, E. (2003) · Journal of Andrology · doi:10.1002/j.1939-4640.2003.tb02739.x · Cited by 18
Self-citationZitzmann, M., & Nieschlag, E. (2001) · Cambridge University Press eBooks · doi:10.1017/cbo9780511545221.010 · Cited by 15
Self-citationThe androgen receptor: molecular biology
Klocker, H., Gromoll, J., & Cato, A. C. B. (2001) · Cambridge University Press eBooks · doi:10.1017/cbo9780511545221.003 · Cited by 12
Wistuba, J., Luetjens, C. M., Kamischke, A., Gu, Y., Schlatt, S., Simoni, M., & Nieschlag, E. (2005) · Journal of Medical Primatology · doi:10.1111/j.1600-0684.2005.00115.x · Cited by 11
Self-citationMEDICAL EDUCATION AND GOVERNMENT IN IRELAND.
Carmichael (1831) · The Lancet · doi:10.1016/s0140-6736(02)94053-5 · Cited by 2
Cited by
Sorted by citations
Investigation, treatment and monitoring of late-onset hypogonadism in males
Wang, C., Nieschlag, E., Swerdloff, R., Behre, H. M., Hellstrom, W. J., Gooren, L. J., Kaufman, J. M., Legros, J.-J., Lunenfeld, B., Morales, A., et al. (2008) · European Journal of Endocrinology · doi:10.1530/eje-08-0601 · Cited by 867
Self-citationTestosterone: a metabolic hormone in health and disease
Kelly, D. M., & Jones, T. H. (2013) · Journal of Endocrinology · doi:10.1530/joe-12-0455 · Cited by 612
Kelly, D. M., & Jones, T. H. (2015) · Obesity Reviews · doi:10.1111/obr.12282 · Cited by 487
Wang, C., Nieschlag, E., Swerdloff, R. S., Behre, H. M., Hellstrom, W. J. G., Gooren, L. J., Kaufman, J., Legros, J. J., Lunenfeld, B., Morales, Á., et al. (2008) · Journal of Andrology · doi:10.2164/jandrol.108.006486 · Cited by 443
Self-citationThe benefits and risks of testosterone replacement therapy: a review
Morley, J. E. (2009) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s3025 · Cited by 381
Metadata
- Authors
- Zitzmann, M., & Nieschlag, E.
- Affiliations
- University Hospital Münster (DE)
- Corresponding author
- Nieschlag, Eberhard
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2007-10-01
- Volume
- 92
- Issue
- 10
- Pages
- 3844-3853
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2127886125
- Cited by
- 216
- References
- 60
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 9 · 2023: 12 · 2022: 2 · 2021: 6 · 2020: 3 · 2019: 8 · 2018: 4 · 2017: 10 · 2016: 9 · 2015: 17 · 2014: 19 · 2013: 15 · 2012: 10
- FWCI
- 16.08
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Keywords
- testosterone undecanoate, androgen receptor gene, CAG repeat length, hypogonadism, testosterone replacement therapy, body mass index, obesity, pharmacogenetics, lipid profile, blood pressure, erythropoiesis, hematocrit, prostate
- MeSH terms
- Adult, Humans, Hypogonadism, Injections, Intramuscular, Male, Middle Aged, Obesity, Pharmacogenetics, Receptors, Androgen, Regression Analysis, Testosterone, Body Mass Index, Nonlinear Dynamics, Trinucleotide Repeats, Testosterone Congeners
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
